Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:50:48.905Z.
Calculation as of: 2026-10-06T12:50:48.905Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.52B
EV/Sales Ratio
14.45x
TTM Avg
10.18x
3Y Avg
7.41x
5Y Avg
6.19x
Market Cap
$1.45B
EV/Sales Ratio
0.70x
TTM Avg
0.73x
3Y Avg
0.58x
5Y Avg
0.61x
Market Cap
$1.43B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
EV/Sales Ratio
N/A
TTM Avg
781.47x
3Y Avg
902.36x
5Y Avg
638.00x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.52B | 2.76x | 3.82x | 4.31x | 4.24x |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 14.45x | 10.18x | 7.41x | 6.19x |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 6.70x | 6.81x | 12.09x | 18.83x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 0.70x | 0.73x | 0.58x | 0.61x |
| Certara, Inc. (CERT)vs › | $1.57B | 4.10x | 3.18x | 5.10x | 7.42x |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | 781.47x | 902.36x | 638.00x |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 2.62x | 3.21x | 3.51x | 4.10x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
